allergic rhinitis
Immunology · 2016–2016
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| Dactylis glomerata with Poa pratensis with Lolium perenne with Anthoxanthum odoratum and Phleum pratense Treatment of moderate to severe allergic rhinitis/rhinoconjunctivitis caused by grass pollen in adults, adolescents and children above 5 years who have failed… | Jul 2016 | Not recommended | input received Anaphylaxis Australia |
| house dust mite allergen extract (American with European) Treatment of allergic rhinitis caused by house dust mites in adults and adolescents aged 12 years and above with moderate to severe disease inadequately… | Jul 2016 | Not recommended | input received Anaphylaxis Australia |
Who spoke
Anaphylaxis Australia
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| american house dust mite extract + european house dust mite extractACARIZAX (American house dust mite extract and European house dust mit | 2006 | 5 |
| ciclesonideALVESCO ciclesonide 160 micrograms per actuation aerosol can | 2004 | 3 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.